Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 1.00 |
| ▸ | HTR1A | P08908 | 12/20 | 1.00 |
| ▸ | HTR2A | P28223 | 11/20 | 1.00 |
| ▸ | HTR7 | P34969 | 11/20 | 1.00 |
| ▸ | HTR6 | P50406 | 11/20 | 1.00 |
| ▸ | DRD4 | P21917 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipsapirone SCHEMBL29356316 | 1.00 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR7HTR6 | |
| Ipsapirone SCHEMBL121856 | 0.99 | DRD2 (0.98) | DRD2HTR1AHTR2AHTR7HTR6 | |
| Revospirone SCHEMBL1932725 | 0.98 | HTR1A (1.00) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL9400845 | 0.93 | HTR1A (0.87) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL9480697 | 0.89 | HTR1A (0.80) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL9480686 | 0.89 | DRD2 (0.80) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL9400972 | 0.89 | DRD2 (0.80) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL9400978 | 0.88 | DRD2 (0.78) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL9480100 | 0.86 | DRD2 (0.76) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL9481387 | 0.86 | HTR1A (0.75) | DRD2HTR1AHTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7475 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| US-20240252535-A1 | CELLULAR COMPOSITION FOR TREATMENT OF DISEASES, DISORDERS OR CONDITIONS AND METHOD OF USE | YZTHERAPEUTIC PERFORMANCE LTD. (IL) | 2024-08-01 | — | — | US | claimed |
| EP-4335504-A2 | TREATMENT OF MOVEMENT DISORDERS | Contera Pharma ApS (DK) | 2024-03-13 | — | — | EP | claimed |
| EP-3897641-B1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA AS (DK) | 2023-11-15 | — | — | EP | claimed |
| EP-4208177-A1 | CELLULAR COMPOSITION FOR TREATMENT OF DISEASES, DISORDERS OR CONDITIONS AND METHOD OF USE | Yztherapeutic Performance Ltd. (IL) | 2023-07-12 | — | — | EP | claimed |
| US-20220273600-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2022-09-01 | — | — | US | claimed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-20220062279-A1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA A/S (DK) | 2022-03-03 | — | — | US | claimed |
| EP-3897641-A1 | TREATMENT OF MOVEMENT DISORDERS | Contera Pharma A/S (DK) | 2021-10-27 | — | — | EP | claimed |
| WO-1993024144-A1 | PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-α AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY | SYNTELLO INC. (US) | 1993-12-09 | — | — | WO | claimed |
| US-5258379-A | ADMINISTERING IN AN EFFECTIVE DOSAGE TO MAMMALS | ELI LILLY AND COMPANY (US) | 1993-11-02 | — | — | US | claimed |
| EP-0565274-A1 | 5-Ht1A agonists for improving primary memory and/or learning | ELI LILLY AND COMPANY (US) | 1993-10-13 | — | — | EP | claimed |
| US-5185329-A | Azapirone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-02-09 | — | — | US | claimed |
| EP-0314984-B1 | USE OF 2-PYRIMIDINYL-1-PIPERAZINE DERIVATIVES | Troponwerke GmbH & Co. KG (DE) | 1992-12-02 | — | — | EP | claimed |
| EP-0303951-B1 | 2-PYRIMIDINYL-1-PIPERAZINE DERIVATIVES FOR TREATING ALCOHOLISM | Troponwerke GmbH & Co. KG (DE) | 1992-11-04 | — | — | EP | claimed |
| EP-0510837-A2 | Synergistic combinations in the treatment of anxiety | PFIZER INC. (US) | 1992-10-28 | — | — | EP | claimed |
| EP-0455510-A2 | Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion | ELI LILLY AND COMPANY (US) | 1991-11-06 | — | — | EP | claimed |
| EP-0442424-A1 | Treatment of sleep apneas with azapirone derivatives | Bristol-Myers Squibb Company (US) | 1991-08-21 | — | — | EP | claimed |
| EP-0356997-A2 | The use of buspirone for preparing pharmaceutical compositions for the treatment of substance addiction | Bristol-Myers Squibb Company (US) | 1990-03-07 | — | — | EP | claimed |